Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial-Reference-Cited by-同舟云学术

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

Published:2024-02-26 Issue:1 Volume:29 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Salwender Hans¹^ORCID,Weinhold Niels²,Benner Axel³,Miah Kaya³,Merz Maximilian⁴,Haenel Mathias⁵,Jehn Christian⁶,Mai Elias²,Menis Ekaterina²,Blau Igor⁷,Scheid Christof⁸,Hose Dirk⁹,Seckinger Anja⁹,Luntz Steffen¹⁰,Besemer Britta¹¹,Munder Markus¹²,Brossart Peter¹³,Glass Bertram¹⁴,Lindemann Hans-Walter¹⁵,Weisel Katja¹⁶,Hanoun Christine¹⁷,Schnitzler Paul¹⁸,Klemm Sarah¹⁸,Goldschmidt Hartmut²¹⁹,Raab Marc²,Elmaagacli Ahmet⁶

Affiliation:

1. Department of Oncology and Hematology, Asklepios Hospital Hamburg Altona, Hamburg, Germany

2. Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany

3. Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany

4. Department of Hematology and Cell Therapy, University Hospital Leipzig, Leipzig, Germany

5. Department of Oncology and Hematology, Klinikum Chemnitz, Chemnitz, Germany

6. Department of Hematology/Oncology and Stem Cell Transplantation, AK St. Georg, Hamburg, Germany

7. Department of Oncology and Hematology, Charité Universitätsmedizin, Berlin, Germany

8. Department of Oncology and Hematology, University Hospital Cologne, Cologne, Germany

9. Laboratory of Hematology and Immunology & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium

10. Department of Oncology and Hematology, Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany

11. Department of Oncology and Hematology, University Hospital Tubingen, Tubingen, Germany

12. Department of Oncology and Hematology, University Medical Center Mainz, Mainz, Germany

13. Department of Oncology and Hematology, University Hospital Bonn, Bonn, Germany

14. Department of Oncology and Hematology, Helios Hospital Berlin Buch, Buch, Germany

15. Department of Oncology and Hematology, Kath. Krankenhaus Hagen, Hagen, Germany

16. Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

17. Department of Oncology and Hematology, University Hospital Essen, Essen, Germany

18. Zentrum für Infektiologie, Virologie Universitätsklinikum Heidelberg, Heidelberg, Germany

19. Department of Oncology and Hematology, National Center for Tumor Diseases (NCT), Heidelberg, Germany

Funder

Celgene

Chugai Pharmaceutical

Janssen Pharmaceutica

Binding Site

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2024.2320006

Reference21 articles.

1. Immunosuppressive effects of beta-herpesviruses;Boeckh M;Herpes,2003

2. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

3. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation

4. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

5. High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV)–Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effects of Primary CMV Infection